President Makes NCAB Appointments

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 8
Volume 5
Issue 8

WASHINGTON--President Clin-ton has reappointed Barbara K. Rimer, DrPH, to a second 2-year term as chair of the National Cancer Advisory Board (NCAB) and appointed Richard J. Boxer, MD, professor of family and community medicine, Medical College of Wisconsin, Milwaukee, to a full 6-year term. Dr. Boxer had served on the board for a year to complete the term of Paul Calabresi, MD, who resigned to join the President's Cancer Panel.

WASHINGTON--President Clin-ton has reappointed Barbara K. Rimer,DrPH, to a second 2-year term as chair of the National CancerAdvisory Board (NCAB) and appointed Richard J. Boxer, MD, professorof family and community medicine, Medical College of Wisconsin,Milwaukee, to a full 6-year term. Dr. Boxer had served on theboard for a year to complete the term of Paul Calabresi, MD, whoresigned to join the President's Cancer Panel.

The President also appointed four new members: Frederick P. Li,MD, head of the Division of Cancer Epidemiology, Dana-Farber CancerInstitute; Ivor Royston, MD, president and CEO of the Sidney KimmelCancer Center, San Diego; Ellen L. Stovall, executive directorof the National Coalition for Cancer Survivorship; and SandraMillon-Underwood, PhD, associate professor, University of Wisconsin,Milwaukee.

Related Videos
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
A panel of 4 experts on multiple myeloma seated at a long table
A panel of 4 experts on multiple myeloma seated at a long table
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
The difference in adverse effect profiles between sorafenib and nirogacestat may make one treatment more appealing than the other for certain patients with desmoid tumors, says Brian Van Tine, MD, PhD.
Related Content